Takeda Pharmaceuticals Agrees to Pay $13.6 Million to Resolve Alleged Kickback Scheme Involving Antidepressant Drug

Last week, the U.S. Department of Justice announced that Takeda Pharmaceuticals USA had agreed to pay approximately $13.6 million to resolve allegations that it violated the False Claims Act by providing improper payments to healthcare providers tied to prescriptions of Trintellix, an antidepressant medication used to treat major depressive disorder.

According to the DOJ, the government alleged that Takeda paid physicians through speaker programs and related events that were intended to induce prescriptions of Trintellix, resulting in claims submitted to Medicare and other federal healthcare programs. The settlement resolves the allegations without an admission of liability.

The resolution is another reminder that federal enforcement agencies continue to closely scrutinize pharmaceutical speaker programs, consulting arrangements, and other financial relationships with referral sources under the Anti-Kickback Statute and the FCA. In recent years, the DOJ and HHS-OIG have repeatedly emphasized that payments tied—even indirectly—to prescribing behavior remain a significant enforcement priority.

Healthcare companies should ensure that speaker programs and advisory arrangements serve a legitimate educational or business purpose, are appropriately documented, and are structured to comply with federal fraud and abuse laws.

The settlement also highlights the government’s continued focus on so-called “high-prescribing” physicians and repeat-attendee speaker programs. Enforcement agencies have increasingly viewed programs with little educational value, lavish meals, or attendance by the same providers multiple times as potential indicators that the events are being used primarily as marketing tools rather than legitimate educational forums. Pharmaceutical and medical device companies should periodically audit these arrangements to confirm that compensation is fair market value, attendance is appropriate, and programs are supported by legitimate clinical content.

In addition, the case serves as another example of how AKS allegations can quickly evolve into substantial FCA exposure. Because claims submitted to federal healthcare programs that allegedly result from kickbacks may be deemed “false” under the FCA, even relatively narrow compliance issues can create significant financial exposure, including treble damages and statutory penalties. As DOJ enforcement activity in the healthcare sector continues to increase, providers, manufacturers, and healthcare entities should remain proactive in reviewing compliance policies, training programs, and financial relationships with referral sources.

GWB represents businesses and individuals in the healthcare industry in connection with government investigations and litigation, including under the False Claims Act. If you need assistance with such a matter, please contact us.